ACPE Universal
Program Number: 207-000-07-007-H01
Release Date: July 1, 2007
Expiration Date: July 1, 2010
Description
In 2006, the Food and Drug Administration approved 18 new molecular
entities, several new biologicals, and numerous new dosage forms.
This article provides an overview of 11 of the new entities, highlighting
important information about their mechanism of action, pharmacokinetic
profile, effectiveness, dosing information, and potential side
effects and adverse reactions.
Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:
- Review
the content of the activity.
- Successfully complete the post-test (70% or higher).
- You will have
two (2) opportunities to successfully complete the activity.
Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.
Fee
There is no fee for this activity.
Accreditation
Pharmacists
NCPA
is approved by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education. This program will
provide 2.0 contact hours (.2 CEUs) of continuing pharmacy education
credit under the number 207-000-07-007-H01.
Faculty
Ann McMahon
Wicker, PharmD, BCPS, is an assistant professor of clinical
pharmacy practice; Roxie Stewart, PharmD, is a pharmacy care
lab instructor; and Connie Smith, BS Pharm, is the
coordinator of experiential education, all at the University of
Louisiana at Monroe College of Pharmacy, Monroe, Louisiana.
Disclosure
Declaration
It is the policy of the National Community Pharmacists
Association (NCPA) to ensure independence, balance, objectivity,
scientific rigor, and integrity in all of their continuing education
activities.
The author,
sponsor, and publisher of this continuing education activity have
made all reasonable efforts to ensure that information contained
herein is accurate in accordance with the latest available scientific
knowledge at the time of accreditation of this continuing education
program. Information regarding drugs (e.g., their administration,
dosages, contraindications, adverse reactions, interactions, special
warnings, precautions) and drug delivery systems are subject to
change, however, and the reader is advised to check the manufacturer's
package insert for information concerning recommended dosage and
potential problems or cautions prior to dispensing or administering
the drug or using the drug delivery systems.
Approval of credit for this continuing education activity does not
imply endorsement by NCPA of any product or manufacturer identified.
Any medications or treatment methods suggested in this CE activity
should not be used by the practitioner without evaluation of their
patient's condition(s) and possible contraindication(s) or danger(s)
of use of any specific medication.
Software
Requirements